Latvia
Hepatitis B
Download HBV dataPrevalence of chronic HBV (HBsAg+)
National
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 1.46 (0.17 - 12.10) | 2015 | Modelled | WHO |
| 0.54 (0.46 - 0.61) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
| 0.6 (0.52 - 0.68) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.62 (0.53 - 0.70) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.62 (0.54 - 0.69) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.62 (0.53 - 0.70) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.63 (0.54 - 0.70) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.65 (0.56 - 0.72) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.66 (0.58 - 0.74) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.68 (0.59 - 0.77) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.69 (0.60 - 0.78) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.71 (0.61 - 0.80) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.73 (0.63 - 0.82) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.75 (0.65 - 0.84) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.77 (0.66 - 0.86) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.78 (0.67 - 0.88) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.79 (0.68 - 0.88) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.8 (0.69 - 0.90) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.82 (0.70 - 0.93) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.84 (0.72 - 0.95) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.86 (0.72 - 0.97) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.87 (0.74 - 0.98) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.89 (0.77 - 1) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.92 (0.79 - 1.03) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.94 (0.81 - 1.05) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.94 (0.81 - 1.07) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.94 (0.82 - 1.06) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.94 (0.82 - 1.06) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.94 (0.81 - 1.05) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.93 (0.81 - 1.05) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.92 (0.80 - 1.04) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.57 (0.49 - 0.65) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
Children under-5 years
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 0.51 (0.06 - 4.68) | 2015 | Modelled | WHO |
| 0.05 (0.04 - 0.06) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
| 0.07 (0.06 - 0.09) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.07 (0.06 - 0.09) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.07 (0.06 - 0.09) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.07 (0.06 - 0.09) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.07 (0.06 - 0.09) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.08 (0.06 - 0.10) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.09 (0.07 - 0.11) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.11 (0.09 - 0.13) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.12 (0.10 - 0.15) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.13 (0.10 - 0.15) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.12 (0.10 - 0.15) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.12 (0.09 - 0.14) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.11 (0.08 - 0.13) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.1 (0.08 - 0.12) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.09 (0.07 - 0.11) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.1 (0.08 - 0.12) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.11 (0.09 - 0.13) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.13 (0.10 - 0.15) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.15 (0.12 - 0.19) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.18 (0.14 - 0.22) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.32 (0.26 - 0.39) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.61 (0.49 - 0.74) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.95 (0.76 - 1.14) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.22 (0.98 - 1.48) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.34 (1.07 - 1.63) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.34 (1.07 - 1.63) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.33 (1.07 - 1.62) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.33 (1.06 - 1.61) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.31 (1.05 - 1.61) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.29 (1 - 1.61) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.27 (0.12 - 0.56) | 2020 | Modelled | WHO |
Showing out of
Show more
People who inject drugs (PWID)
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 3.6 | 2017 | Survey/reported | EMCDDA |
| 1.42 | 2017 | Survey/reported | ECDC |
| 2.45 | 2016 | Survey/reported | EMCDDA |
| 3.3 | 2015 | Survey/reported | EMCDDA |
| 2.14 | 2014 | Survey/reported | EMCDDA |
| 2.14 | 2013 | Survey/reported | EMCDDA |
| 1.6 | 2012 | Survey/reported | EMCDDA |
Showing out of
Show more
Number of persons living with chronic HBV
National
Download| Value | Year | Type | Source |
|---|---|---|---|
| 10,269 (8,758 - 11,711) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
| 10,464 (8,970 - 11,924) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 11,068 (9,530 - 12,493) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 11,497 (9,875 - 13,017) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 11,675 (10,103 - 13,036) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 11,810 (10,147 - 13,247) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 12,116 (10,457 - 13,500) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 12,552 (10,834 - 13,974) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 13,071 (11,357 - 14,623) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 13,616 (11,768 - 15,311) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 14,074 (12,107 - 15,878) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 14,535 (12,565 - 16,336) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 15,132 (13,117 - 16,985) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 15,789 (13,608 - 17,666) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 16,416 (14,064 - 18,404) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 16,854 (14,431 - 18,981) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 17,233 (14,716 - 19,331) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 17,766 (15,196 - 19,984) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 18,396 (15,732 - 20,709) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 19,045 (16,183 - 21,495) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 19,571 (16,499 - 22,176) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 20,113 (17,140 - 22,678) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 20,848 (17,889 - 23,358) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 21,656 (18,703 - 24,239) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 22,397 (19,371 - 25,113) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 22,908 (19,775 - 25,906) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 23,215 (20,049 - 26,067) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 23,445 (20,288 - 26,267) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 23,549 (20,419 - 26,274) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 23,511 (20,391 - 26,353) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 23,334 (20,112 - 26,206) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
HBV-related death rate
National
Download| Value (per 100,000) | Year | Type | Source |
|---|---|---|---|
| 3.5 (2.50 - 4.81) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
| 3.29 (2.66 - 4) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.46 (2.80 - 4.21) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.66 (2.94 - 4.49) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.35 (3.47 - 5.36) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5.09 (3.98 - 6.40) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5.08 (3.98 - 6.37) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.48 (3.53 - 5.57) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.85 (3.83 - 6.04) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.41 (3.48 - 5.56) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.88 (3.83 - 6.12) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.73 (3.71 - 5.94) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5.49 (4.29 - 6.87) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5.4 (4.26 - 6.74) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5.55 (4.37 - 6.96) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5.71 (4.46 - 7.18) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.19 (4.78 - 7.79) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.6 (5.08 - 8.39) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.24 (4.75 - 7.92) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5.09 (3.90 - 6.49) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.95 (3.03 - 5.11) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.3 (3.27 - 5.54) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.77 (2.90 - 4.87) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.66 (2.79 - 4.74) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.66 (2.80 - 4.73) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.74 (2.86 - 4.83) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.59 (2.73 - 4.69) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.45 (2.62 - 4.54) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.47 (2.56 - 4.70) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.49 (2.56 - 4.75) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.5 (2.50 - 4.81) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
HBV-related deaths
National
Download| Value | Year | Type | Source |
|---|---|---|---|
| 74 | 2016 | Modelled | WHO |
| 87 (71 - 106) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 92 (74 - 112) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 96 (77 - 118) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 131 (103 - 165) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 114 (91 - 140) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 129 (101 - 162) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 112 (89 - 140) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 109 (86 - 138) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 118 (94 - 148) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 114 (90 - 143) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 116 (91 - 146) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 127 (100 - 159) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 128 (100 - 160) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 128 (101 - 161) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 130 (102 - 164) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 138 (105 - 175) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 140 (108 - 176) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 147 (113 - 187) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 111 (85 - 141) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 92 (70 - 119) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 84 (64 - 108) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 79 (60 - 102) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 75 (57 - 98) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 76 (58 - 98) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 68 (52 - 89) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 71 (54 - 93) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 73 (56 - 95) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 68 (50 - 92) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 67 (49 - 92) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 67 (48 - 92) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 67 (48 - 92) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
Showing out of
Show more
Percent of liver cancer deaths attributable to HBV
National
Download
Showing out of
Show more
Coverage of HepB birth dose
Newborns
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 97 | 2009 | Survey/reported | WHO/UNICEF |
| 98 | 2008 | Survey/reported | WHO/UNICEF |
| 97 | 2007 | Survey/reported | WHO/UNICEF |
| 97 | 2006 | Survey/reported | WHO/UNICEF |
| 98 | 2005 | Survey/reported | WHO/UNICEF |
| 99 | 2004 | Survey/reported | WHO/UNICEF |
| 98 | 2003 | Survey/reported | WHO/UNICEF |
| 99 | 2002 | Survey/reported | WHO/UNICEF |
| 99 | 2001 | Survey/reported | WHO/UNICEF |
| 98 | 2000 | Survey/reported | WHO/UNICEF |
Showing out of
Show more
Coverage of 3-dose hepatitis B vaccine
Infants
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 99 | 2019 | Survey/reported | WHO/UNICEF |
| 99 | 2020 | Survey/reported | WHO/UNICEF |
| 94 | 2021 | Survey/reported | WHO/UNICEF |
Showing out of
Show more
Number of needles/syringes per PWID per year
People who inject drugs (PWID)
Download| Value | Year | Type | Source |
|---|---|---|---|
| 108 | 2017 | Survey/reported | EMCDDA, 2019 |
| 37 (29 - 47) | 2015 | Survey/reported | EMCDDA 2017 |
| 108 | 2017 | Survey/reported | ECDC |
Showing out of
Show more
Percent of PWID accessing OST
People who inject drugs (PWID)
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 9 | 2017 | Survey/reported | EMCDDA, 2019 |
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
Yes (for risk groups)
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
Yes
% of substance use disorder facilities offering hepatitis testing
Many (31-60%)
% of substance use disorder facilities offering hepatitis treatment
None
Hepatitis C
Download HCV dataPrevalence of chronic HCV (RNA+/cAg)
National
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 2.2 (1.40 - 2.60) | 2015 | Modelled | Blach et al, 2017 |
| 1.93 (1.58 - 2.36) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.94 (1.58 - 2.36) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.94 (1.56 - 2.37) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.94 (1.58 - 2.35) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.94 (1.60 - 2.38) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.93 (1.60 - 2.36) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.93 (1.59 - 2.33) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.92 (1.59 - 2.32) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.92 (1.58 - 2.32) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.91 (1.57 - 2.31) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.91 (1.58 - 2.30) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.91 (1.58 - 2.31) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.91 (1.58 - 2.32) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.91 (1.57 - 2.33) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.91 (1.57 - 2.34) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.91 (1.57 - 2.34) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.91 (1.58 - 2.33) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.92 (1.57 - 2.35) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.92 (1.57 - 2.36) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.91 (1.56 - 2.37) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.89 (1.54 - 2.32) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.86 (1.52 - 2.29) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.84 (1.50 - 2.25) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.81 (1.47 - 2.24) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.8 (1.45 - 2.21) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.79 (1.45 - 2.20) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.79 (1.45 - 2.20) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.79 (1.45 - 2.19) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.8 (1.45 - 2.21) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.81 (1.46 - 2.23) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.84 (1.51 - 2.25) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
Showing out of
Show more
People who inject drugs (PWID)
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 52.49 | 2016 | Survey/reported | EMCDDA |
| 48.6 | 2015 | Survey/reported | EMCDDA |
| 63.7 | 2014 | Survey/reported | EMCDDA |
| 70.1 | 2013 | Survey/reported | EMCDDA |
| 74.2 | 2012 | Survey/reported | EMCDDA |
| 56.99 | 2010 | Survey/reported | EMCDDA |
| 35.94 | 2009 | Survey/reported | EMCDDA |
Showing out of
Show more
Women of childbearing age (15–49 years)
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 2.07 (1.34 - 2.40) | 2019 | Modelled | Dugan et al., 2021 |
Prevalence of anti-HCV
National
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 2.4 (1.70 - 3.30) | 2008 | Survey/reported | Tolmane I et al, 2011 |
| 2.4 (1.70 - 3.30) | 2014 | Survey/reported | Gower et al, 2014 |
| 2.4 (1.70 - 3.30) | 2008 | Survey/reported | ECDC |
Showing out of
Show more
People who inject drugs (PWID)
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 74.4 (67.60 - 81.20) | 2014 | Modelled | Degenhardt L et al, 2017 |
| 70.1 (66 - 74) | 2013 | Survey/reported | EMCDDA |
| 85.2 | 2017 | Survey/reported | EMCDDA |
| 56.78 | 2017 | Survey/reported | ECDC |
Showing out of
Show more
Number of persons living with chronic HCV (RNA+/cAg)
National
Download| Value | Year | Type | Source |
|---|---|---|---|
| 43,000 (28,000 - 50,000) | 2015 | Modelled | Blach et al, 2017 |
| 45,732 (36,894 - 56,438) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 45,312 (36,725 - 55,542) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 44,917 (36,319 - 55,013) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 44,498 (36,070 - 54,694) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 44,025 (35,655 - 54,326) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 43,583 (35,277 - 53,824) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 43,379 (35,139 - 53,503) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 43,423 (35,287 - 53,335) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 43,535 (35,363 - 53,424) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 43,614 (35,562 - 53,608) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 43,588 (35,536 - 54,063) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 43,325 (35,319 - 53,331) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 42,848 (35,143 - 52,403) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 42,281 (34,952 - 51,741) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 41,712 (34,384 - 51,073) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 41,220 (33,863 - 50,559) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 40,769 (33,621 - 49,751) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 40,292 (33,289 - 49,034) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 39,818 (32,847 - 48,297) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 39,331 (32,389 - 47,452) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 38,806 (31,857 - 46,945) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 38,294 (31,565 - 46,322) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 37,853 (31,235 - 45,784) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 37,470 (31,019 - 45,426) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 37,123 (30,642 - 45,333) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 36,804 (30,277 - 45,107) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 36,468 (29,826 - 44,333) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 36,122 (29,106 - 44,189) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 35,760 (29,200 - 43,708) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 35,192 (28,851 - 43,030) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
| 35,347 (28,992 - 43,191) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
Women of childbearing age (15–49 years)
Download| Value | Year | Type | Source |
|---|---|---|---|
| 8,300 (5,400 - 9,600) | 2019 | Modelled | Dugan et al., 2021 |
HCV-related death rate
National
Download| Value (Deaths per 100,000) | Year | Type | Source |
|---|---|---|---|
| 5.09 (3.75 - 6.85) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
| 2.16 (1.69 - 2.83) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.32 (1.81 - 3.04) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.54 (1.97 - 3.29) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.69 (2.80 - 4.82) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.1 (2.38 - 4.07) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.78 (2.89 - 4.90) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.48 (2.70 - 4.47) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.55 (2.75 - 4.52) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.93 (3.05 - 5.03) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.02 (3.15 - 5.16) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.9 (3.03 - 4.97) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.42 (3.45 - 5.66) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.51 (3.52 - 5.75) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.59 (3.57 - 5.87) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.71 (3.70 - 6.02) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5.94 (4.56 - 7.66) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5.65 (4.35 - 7.32) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5.1 (3.95 - 6.55) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5.64 (4.36 - 7.23) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5.56 (4.33 - 7.13) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5.56 (4.33 - 7.15) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5.44 (4.25 - 6.98) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5.35 (4.19 - 6.88) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5.52 (4.34 - 7.10) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5.36 (4.19 - 6.92) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5.43 (4.25 - 6.97) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5.1 (3.97 - 6.60) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5.07 (3.83 - 6.72) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5.08 (3.78 - 6.87) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5.09 (3.75 - 6.85) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
HCV-related deaths
National
Download| Value | Year | Type | Source |
|---|---|---|---|
| 192 | 2016 | Modelled | WHO |
| 97 (72 - 131) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 97 (72 - 131) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
| 98 (73 - 133) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 99 (75 - 131) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 100 (78 - 130) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 107 (83 - 138) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 109 (85 - 140) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 112 (88 - 144) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 110 (86 - 141) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 113 (89 - 146) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 118 (92 - 151) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 119 (93 - 153) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 123 (95 - 157) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 131 (101 - 169) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 126 (97 - 163) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 115 (89 - 148) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 107 (84 - 137) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 106 (82 - 135) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 105 (82 - 134) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 104 (81 - 133) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 96 (75 - 123) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 94 (73 - 120) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 96 (75 - 123) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 88 (68 - 112) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 87 (68 - 112) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 96 (73 - 125) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 95 (72 - 124) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 81 (62 - 106) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 67 (52 - 87) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 62 (48 - 80) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 57 (45 - 75) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
Percent of liver cancer deaths attributable to HCV
National
Download
Showing out of
Show more
Number of persons treated for HCV
National
Download| Value | Year | Type | Source |
|---|---|---|---|
| 1,300 | 2017 | Survey/reported | ECDC, 2019 |
| 1,300 | 2017 | Survey/reported | The European Centre for Disease Prevention and Control, 2019 |
Showing out of
Show more
Number of needles/syringes per PWID per year
People who inject drugs (PWID)
Download| Value | Year | Type | Source |
|---|---|---|---|
| 108 | 2017 | Survey/reported | EMCDDA, 2019 |
| 37 (29 - 47) | 2015 | Survey/reported | EMCDDA 2017 |
| 108 | 2017 | Survey/reported | ECDC |
Showing out of
Show more
Percent of PWID accessing OST
People who inject drugs (PWID)
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 9 | 2017 | Survey/reported | EMCDDA, 2019 |
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
Yes (for risk groups)
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
Yes
% of substance use disorder facilities offering hepatitis testing
Many (31-60%)
% of substance use disorder facilities offering hepatitis treatment
None
Overview
HBV elimination goal
HCV elimination goal
Prevalence (national)
Modelled
Survey/surveillance
No data available
Hepatitis related deaths (national)
Modelled
HBV
67
2019
(48 - 92)
IHME, GBD 2019 (accessed 2020)
Survey/surveillance
No data available
HBV chart
Modelled
HCV
97
2019
(72 - 131)
IHME, GBD 2019 (accessed 2022)
Survey/surveillance
No data available
HCV chart
Prevalence < 5
HBV
0.27
(%)
2020, latest modelled
(0.12 - 0.56(%))
WHO
Prevalence PWID
HCV
85.20
(%)
2017, survey/surveillance
EMCDDA
Eligible for HBV generic medicines
Eligible for HCV generic medicines
